Annals of Oncology最新文献

{"title":"Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments-analysis of 11 trials by AIO and GONO.","authors":"M M Germani, V Heinemann, D Rossini, L Fischer von Weikersthal, F Pietrantonio, K Heinrich, A Stahler, S Lonardi, F Kaiser, T Decker, L Salvatore, L Weiss, F Morano, M Fuchs, F Bergamo, C Antoniotti, G Masi, S Stintzing, P Frumento, C Cremolini, D P Modest","doi":"10.1016/j.annonc.2025.08.001","DOIUrl":"10.1016/j.annonc.2025.08.001","url":null,"abstract":"<p><strong>Background: </strong>We evaluated the distribution and risk of disease progression (PD) in first-line therapy of unresected metastatic colorectal cancer (mCRC) patients receiving chemotherapy + biologics. The aim of the analysis is to provide guidance for the timing of disease reassessments during first-line therapy.</p><p><strong>Patients and methods: </strong>Individual data of 2939 unresected patients from TRIBE, MOMA, TRIBE2, VALENTINO, ATEZOTRIBE, TRIPLETE, FIRE-3, XELAVIRI, PANAMA, FIRE-4 and FIRE-4.5 were analyzed. The frequency and risk of PD events were calculated for individual timepoints during therapy. RAS/BRAF profiling, tumor sidedness, type of therapy and early tumor shrinkage (ETS) were used to identify subgroups for risk assessment. A Cox regression model to predict first-line progression-free survival (PFS) was built.</p><p><strong>Results: </strong>In the overall population, the maximum frequency of PD events was observed at 7.6 months, with an absolute PD risk of 19%. Then, the PD risk flattened, achieving a maximum of 23% at 14 months in RAS/BRAF-wild-type patients (n = 1786), 25% at 10 months in RAS-mutant patients (n = 973) and 35% at 8 months in BRAF-mutant patients (n = 180). Eastern Cooperative Oncology Group performance status >0, right-sidedness, initially unresected primary tumor, higher number of organs involved by metastases and BRAF mutation were independently associated with a higher risk of PD in first line. The impact of baseline characteristics on PFS was mitigated after incorporation of ETS in the model.</p><p><strong>Conclusions: </strong>The distribution of PD events does not follow a Gaussian pattern, with the highest density observed between the third and fourth reassessment of a bimonthly surveillance schedule. In clearly unresectable patients, restaging should focus on the interval between 6 and 10 months and not on the initiation of systemic therapy. Our model might be helpful to schedule radiological reassessments according to baseline characteristics, early response and the expected duration of each treatment efficacy.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":65.4,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144939708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence trends and long-term survival in early-onset colorectal cancer: a nationwide Swedish study.","authors":"S Barot, A Liljegren, C Nordenvall, J Blom, C Radkiewicz","doi":"10.1016/j.annonc.2025.07.019","DOIUrl":"10.1016/j.annonc.2025.07.019","url":null,"abstract":"<p><strong>Background: </strong>Early-onset colorectal cancer (EOCRC, diagnosis before age 50) is increasing globally. Survival comparisons with late-onset colorectal cancer (CRC) are inconsistent, however, and long-term excess mortality remains poorly understood. This Swedish population-based study aimed to evaluate trends in incidence, survival, and long-term excess mortality in early- versus late-onset CRC.</p><p><strong>Materials and methods: </strong>We identified all incident colorectal adenocarcinomas recorded in the Swedish National Cancer Register from 1993 to 2019. Incidence trends were quantified using annual percentage changes and relative survival differences were assessed using excess mortality rate ratios, both from Poisson regression models with 95% confidence intervals (CIs).</p><p><strong>Results: </strong>A total of 47 864 right-sided colon, 40 664 left-sided colon, and 47 082 rectal cancer cases were included. EOCRC patients were more frequently diagnosed with metastatic disease, compared with late-onset CRC. EOCRC incidence increased across all subsites, with annual percentage changes ranging from 2.04 (95% CI 1.51-2.56) for rectal to 2.64 (95% CI 2.02-2.37) for right-sided colon cancer, while an increase among late-onset cases was observed only for right-sided colon cancer. Crude 5-year relative survival was similar across age groups, but after full adjustment (including metastatic stage), EOCRC was associated with better survival, with excess mortality rate ratios ranging from 0.76 (95% CI 0.68-0.84) for rectal cancer to 0.83 (95% CI 0.74-0.92) for right-sided colon cancer. Notably, excess mortality remained elevated 5-10 years after diagnosis in both age groups.</p><p><strong>Conclusions: </strong>EOCRC incidence is increasing in Sweden, aligning with global trends. Although younger patients were more often diagnosed at an advanced stage of disease, they had similar crude survival and better stage-adjusted survival, compared with older patients. The persistent long-term excess mortality in both groups, even during periods when CRC patients are typically considered statistically cured, highlights the need for extended follow-up and tailored survivorship care.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":65.4,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144858818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline.","authors":"D Trapani, D Martins-Branco, G Curigliano, A Gennari, G Pentheroudakis, N Harbeck","doi":"10.1016/j.annonc.2025.07.017","DOIUrl":"https://doi.org/10.1016/j.annonc.2025.07.017","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":65.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imatinib’s last lessons? A roadmap to cure","authors":"A. Napolitano ,&nbsp;A. De Vita ,&nbsp;R.L. Jones","doi":"10.1016/j.annonc.2025.07.012","DOIUrl":"10.1016/j.annonc.2025.07.012","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 9","pages":"Pages 1005-1006"},"PeriodicalIF":65.4,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials.","authors":"M Graeser, O Gluz, C Zu Eulenburg, S Kuemmel, R von Schumann, M Christgen, R Wuerstlein, E Pelz, H H Kreipe, P Schmid, M Thill, M Braun, J Potenberg, C Schumacher, J Tio, J Schumacher, L Wujak, A D Hartkopf, M Just, C Schem, K Luedtke-Heckenkamp, F Hilpert, A Kentsch, R E Kates, U Nitz, N Harbeck","doi":"10.1016/j.annonc.2025.07.016","DOIUrl":"10.1016/j.annonc.2025.07.016","url":null,"abstract":"<p><strong>Background: </strong>We analyzed outcomes and survival predictors in three West German Study Group (WSG) randomized de-escalation trials (ADAPT-HR-/HER2+, ADAPT-TP, TP-II) in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC) investigating short (12-week) neoadjuvant treatments with or without chemotherapy.</p><p><strong>Patients and methods: </strong>A total of 713 patients were analyzed; neoadjuvant chemotherapy (paclitaxel plus pertuzumab plus trastuzumab): n = 149, neoadjuvant chemotherapy-free (pertuzumab plus trastuzumab, trastuzumab-only)/antibody-drug conjugate (ADC, trastuzumab emtansine) treatment: n = 564. Patients with pathological complete response (pCR, ypT0/is ypN0) were allowed to omit further chemotherapy; chemotherapy was mandatory after non-pCR. The primary endpoint of each trial was pCR; survival was the secondary endpoint. Survival was analyzed using the Kaplan-Meier method and Cox regression.</p><p><strong>Results: </strong>Median follow-up was 60.7 months. In total, 10 (7%) and 74 (13%) invasive disease-free survival (iDFS) events, 8 (5%) and 51 (9%) distant DFS (dDFS) events, and 6 (4%) and 34 (6%) deaths occurred in the neoadjuvant chemotherapy and chemotherapy-free/ADC groups, respectively; the respective 5-year survival rates were 96% [95% confidence interval (CI) 92% to 99%] and 88% (95% CI 85% to 91%) for iDFS (hazard ratio 0.56, 95% CI 0.29-1.08, P = 0.083) and 98% (95% CI 93% to 99%) and 97% (95% CI 95% to 98%) for overall survival (hazard ratio 0.88, 95% CI 0.36-2.11, P = 0.775). The 5-year iDFS rates in patients with pCR were 98% (95% CI 91% to 99%) after chemotherapy and 94% (95% CI 89% to 97%) after chemotherapy-free/ADC treatment (hazard ratio 0.76, 95% CI 0.27-2.12, P = 0.609). iDFS was comparable between patients with and without adjuvant chemotherapy after pCR to chemotherapy-free/ADC treatment (hazard ratio 1.25, 95% CI 0.39-4.00, P = 0.712). In multivariable analysis, node-negative status and pCR were favorably associated with iDFS in the chemotherapy-free/ADC group.</p><p><strong>Conclusions: </strong>This pooled analysis demonstrates that neoadjuvant de-escalation trials with further pCR-adapted treatment (de-)escalation are feasible and appear safe for HER2-positive eBC patients. Twelve-weekly neoadjuvant paclitaxel plus HER2 blockade is effective and well tolerated. Neoadjuvant chemotherapy-free/ADC treatments can be viable alternatives for stage I-II eBC. Excellent survival after pCR to neoadjuvant chemotherapy-free/ADC treatment lays the groundwork for further de-escalation strategies.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":65.4,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current and future treatments for low-risk gestational trophoblastic neoplasia","authors":"M.J. Seckl,&nbsp;E. Ghorani","doi":"10.1016/j.annonc.2025.07.018","DOIUrl":"10.1016/j.annonc.2025.07.018","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 10","pages":"Pages 1111-1112"},"PeriodicalIF":65.4,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis.","authors":"H S Rugo, E Tokunaga, H Iwata, V Petry, E F Smit, Y Goto, D-W Kim, K Shitara, J F Gruden, S Modi, J Cortés, I Krop, P A Jänne, Y Cheng, C Taitt, F-C Cheng, C A Powell","doi":"10.1016/j.annonc.2025.07.015","DOIUrl":"10.1016/j.annonc.2025.07.015","url":null,"abstract":"<p><strong>Background: </strong>Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate treatment for multiple solid tumors, carries risk of interstitial lung disease/pneumonitis (ILD). Management guidelines generally mandate interrupting T-DXd treatment for grade 1 ILD, with possible retreatment following resolution of imaging findings. This pooled analysis examined T-DXd retreatment duration and ILD recurrence following recovery from grade 1 ILD.</p><p><strong>Patients and methods: </strong>Data were pooled from nine clinical trials of patients with various human epidermal growth factor receptor 2 (HER2)-positive, HER2-low, or HER2 (ERBB2)-mutant solid tumors treated with T-DXd (5.4-8.0 mg/kg). ILD events were reported and graded by investigators and confirmed as drug related by an independent ILD adjudication committee. Patients who recovered from a first investigator-assessed grade 1 and adjudication committee-confirmed drug-related ILD event (ILD1) could receive T-DXd retreatment. Patients were evaluated until disease progression or data cut-off.</p><p><strong>Results: </strong>Among 2145 pooled patients, 9% (193/2145) had grade 1 ILD1, of which 23.3% (45/193) were retreated with T-DXd. Median retreatment duration was 85 days (range 1-848 days); 17.8% (8/45) of patients received T-DXd retreatment for ≥1 year. ILD recurrence (ILD2) occurred in 33.3% (15/45) of retreated patients; median time to ILD2 from T-DXd retreatment was 64 days (range, 22-391 days) and were low-grade events (grade 1, n = 6; grade 2, n = 9; no grade ≥3 or fatal events). Reasons for T-DXd retreatment discontinuation were disease progression [33.3% (15/45)]; ILD recurrence [20% (9/45)]; non-ILD adverse events [17.8% (8/45)]; and physician's decision [4.4% (2/45)]. At the analysis cut-off, 24.4% (11/45) of retreated patients were still receiving treatment, and most patients with ILD2 [60% (9/15)] had recovered with/without sequelae.</p><p><strong>Conclusions: </strong>This first large-scale pooled analysis demonstrates the safety of T-DXd retreatment after recovery from grade 1 ILD. ILD recurred in one-third of patients; all recurrence events were grade 1/2 and manageable using existing treatment guidelines. T-DXd retreatment following resolution of grade 1 drug-related ILD has potential to maximize therapeutic benefit.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":65.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Letter to the Editor “Long-term follow-up of PAOLA-1 and the evolving landscape of post-PARP treatment strategies in ovarian cancer” by Arenhardt and Nogueira-Rodrigues","authors":"I. Ray-Coquard ,&nbsp;C. Cropet ,&nbsp;P. Harter ,&nbsp;E. Pujade-Lauraine ,&nbsp;C. Marth ,&nbsp;D. Pérol","doi":"10.1016/j.annonc.2025.06.017","DOIUrl":"10.1016/j.annonc.2025.06.017","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 10","pages":"Pages 1221-1222"},"PeriodicalIF":65.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144788043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can radiology be first to use prognostic deep learning models for oncological treatment?","authors":"K. Cyll ,&nbsp;O.-J. Skrede ,&nbsp;A. Kleppe","doi":"10.1016/j.annonc.2025.07.013","DOIUrl":"10.1016/j.annonc.2025.07.013","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 10","pages":"Pages 1119-1122"},"PeriodicalIF":65.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.","authors":"T A Eyre, K Cwynarski, F d'Amore, L de Leval, M Dreyling, D A Eichenauer, A J M Ferreri, E Giné, M J Kersten, M Ladetto, L Specht, C Thieblemont, J Walewski, E Zucca, M Jerkeman","doi":"10.1016/j.annonc.2025.07.014","DOIUrl":"10.1016/j.annonc.2025.07.014","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":65.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}